Barr Pharmaceuticals (BRL) Tops Q1 EPS by 4c
More News related to BRL
- Bearclaw Announces Correction to Exercise Price for Grant of Options to Directors
- Bearclaw Announces Grant of Options to Directors
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Top 15 For 2008 (No. 14): M&A Wreckage
- Teva Pharmaceutical (TEVA) and Bar Pharma (BRL) Receives Merger Approval From European Commission
Barr Pharmaceuticals (NYSE: BRL) reports Q1 earnings of $0.78 per share, 4 cents better than estimates. Revenues came in at $332 million versus the consensus of $340 million.
CEO Bruce L. Downey said, "Contraceptive products, both generic and proprietary, continued to be the drivers of sales growth for our Company during the quarter. Proprietary product sales climbed to more than $100 million, a 73% increase over last year, led by our ParaGardŽ IUD, MircetteŽ oral contraceptive and SEASONIQUE(TM) extended-cycle oral contraceptive. Our generic oral contraceptive sales increased 27%, due to the contributions of JolessaŽ, which was launched in the quarter, as well as increased sales of KarivaŽ. While delivering these strong earnings, management also continued its successful pursuit to acquire PLIVA d.d., which closed on October 24, 2006, creating the world's third largest generic pharmaceutical company."
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
